Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Photodynamic therapy for chronic central serous chorioretinopathy
ISRCTN79266681Phase 3Recruiting
- Sponsor
- University of Bristol
- Start
- Jan 2026
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of verteporfin in Central Serous Chorioretinopathy (CSCR) (2 arms), sponsored by University of Bristol. Primary endpoint: Best corrected visual acuity at 12 months. Started Jan 2026; status: recruiting.
02
Drugs
verteporfin
03
Conditions
Central Serous Chorioretinopathy (CSCR)
Beyond the preview
Go deeper on ISRCTN79266681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN79266681.